Veeva Systems Inc.

Revenue comes mostly from subscription fees for ongoing access to its cloud software, with a smaller portion from professional services and consulting billed for implementation and configuration work performed on top of that software. The subscription portion recurs as contracts renew, while the services portion tracks discrete projects and is billed as the work is performed. Recomputed from the company's reported figures, this structure has produced positive net income in every fiscal year CompanyGraph holds on file for it.

CompanyGraph reads the aligned financial ratios here as describing a business that grows mainly by adding subscription customers and expanding what existing ones pay for, funding that growth from its own operating cash rather than leaning on new outside capital. Margins measured at the gross, operating and cash-conversion levels sit in the upper part of its peer range together, retained earnings make up a large share of assets, and cash on hand covers most of total debt. Revenue, gross profit and net income have each grown in every recent year on file, with receivables growing alongside revenue in a pattern consistent with a widening base of billed customers rather than one-off sales. This is a reading of aligned financial ratios, not a claim about what happens next.

Its own account names Amazon Web Services and Salesforce as computing infrastructure it runs on, a Zoom tool it calls critical to one of its meeting products, and Anthropic and Amazon as the sources of the large language models behind its AI features, and it states that these infrastructure relationships cannot easily be switched. Beyond named suppliers, it depends on the life sciences industry itself for nearly all of its revenue, on outside data it acquires, on hosting and subcontractor personnel, and on its own ability to hire and keep skilled employees.

Life-sciences companies depend on this software to run trial, quality, regulatory and commercial processes. Its own filings name large multinational pharmaceutical companies, including Bayer, Eli Lilly, Gilead Sciences and Novartis, among its customers, alongside smaller biotechnology firms, and describe some of its trial-document and quality-content applications as used across nearly all of the largest biopharmaceutical companies. It also states that no single customer accounts for a tenth or more of its revenue in any recent year, describing dependence spread across many customers, even though it separately names dependence on a relatively small number of key customers among its own risk factors.

Its own account describes competing on depth of life-sciences domain expertise, regulatory-compliance functionality built for this industry, and breadth of functionality integrated across development, quality and commercial workflows, alongside ease of deployment, configurability, and the work of integrating with older systems already in place at a customer. Separately, CompanyGraph's map of similarly structured businesses places it among a meaningful number of other companies built around subscription revenue and keeping renewing customers, so this way of operating is not a rare shape. Whether any part of this position is something rivals genuinely cannot copy is not something CompanyGraph can see, since that depends on rivals' own capabilities, which are not on file.

Its own disclosures describe subscription orders that mostly run one year at a time, and multi-year agreements that generally give the customer the right to terminate for convenience, with committed work extending beyond a year described as not significant. This describes short, cancellable commitments rather than long fixed contracts, so the contract terms on file do not point to contract duration as a source of switching friction. What, if anything, makes switching away from this software costly in practice is not disclosed in the material CompanyGraph has read.

Its own account of what limits its growth names customers not renewing or not adopting newer products, its dependence on the life sciences industry for nearly all revenue, competition, capacity or reliability limits at the outside infrastructure it relies on, its ability to hire and retain skilled staff, and the cost of the data and outside AI models its products use. CompanyGraph's general reading of this kind of subscription software business ties its scale to how well it keeps renewing customers relative to the cost of winning new ones; that general frame overlaps with part of this company's own account but does not cover all of it.

It names security breaches or unauthorized access to customer data, intense competition, particularly during its transition of customers off Salesforce-hosted CRM onto its own Vault CRM, and product defects or service disruptions as the risks it emphasizes first. It follows these with weak adoption of newer products, concentration in a relatively small number of key customers, and dependence on the life sciences industry for nearly all revenue. On specific technical dependencies, it names a Zoom tool it calls critical to one of its meeting products, and describes its legacy CRM product as still dependent on Salesforce, a company also named among its competitors, in an infrastructure relationship it says cannot easily be switched.

Its own filings name a specific set of regulatory regimes its software must satisfy, including United States rules for electronic records and manufacturing and clinical systems, European Union rules for computerised systems, and Japanese and international good-practice standards, alongside privacy laws covering the European Union, United Kingdom, United States and China. It also names trade-related pressure, including tariffs, export controls and sanctions, specifically sanctions tied to Russia's invasion of Ukraine that it says could limit payments from Russian banks or bar use of its products in Russia. It reports settling and dismissing a legal dispute with IQVIA Holdings with neither side paying damages, and states it is not otherwise party to proceedings it expects to have a material effect. Because its revenue and costs are earned mostly, but not entirely, in United States dollars, it names remaining exposure to the euro, Japanese yen, Canadian dollar, British pound and Chinese yuan.